Gene-by-environment interactions in Alzheimer's disease and Parkinson's disease
- PMID: 31207254
- PMCID: PMC6700747
- DOI: 10.1016/j.neubiorev.2019.06.018
Gene-by-environment interactions in Alzheimer's disease and Parkinson's disease
Abstract
Diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD) arise from complex interactions of genetic and environmental factors, with genetic variants regulating individual responses to environmental exposures (i.e. gene-by-environment interactions). Identifying gene-by-environment interactions will be critical to fully understanding disease mechanisms and developing personalized therapeutics, though these interactions are still poorly understood and largely under-studied. Candidate gene approaches have shown that known disease risk variants often regulate response to environmental factors. However, recent improvements in exposome- and genome-wide association and interaction studies in humans and mice are enabling discovery of novel genetic variants and pathways that predict response to a variety of environmental factors. Here, we highlight recent approaches and ongoing developments in human and rodent studies to identify genetic modulators of environmental factors using AD and PD as exemplars. Identifying gene-by-environment interactions in disease will be critical to developing personalized intervention strategies and will pave the way for precision medicine.
Keywords: Alzheimer’s disease; Exposome; Gene-Environment; Genetic reference panel; Genome; Parkinson’s disease.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.
Figures

References
-
- Ahmad S, Bannister C, van der Lee SJ, Vojinovic D, Adams HHH, Ramirez A, Escott-Price V, Sims R, Baker E, Williams J, Holmans P, Vernooij MW, Ikram MA, Amin N, and van Duijn CM. 2018. 'Disentangling the biological pathways involved in early features of Alzheimer's disease in the Rotterdam Study', Alzheimers Dement, 14: 848–57. - PubMed
-
- Ahmad S, Rukh G, Varga TV, Ali A, Kurbasic A, Shungin D, Ericson U, Koivula RW, Chu AY, Rose LM, Ganna A, Qi Q, Stancakova A, Sandholt CH, Elks CE, Curhan G, Jensen MK, Tamimi RM, Allin KH, Jorgensen T, Brage S, Langenberg C, Aadahl M, Grarup N, Linneberg A, Pare G, Consortium InterAct, Direct Consortium, Magnusson PK, Pedersen NL, Boehnke M, Hamsten A, Mohlke KL, Pasquale LT, Pedersen O, Scott RA, Ridker PM, Ingelsson E, Laakso M, Hansen T, Qi L, Wareham NJ, Chasman DI, Hallmans G, Hu FB, Renstrom F, Orho-Melander M, and Franks PW. 2013. 'Gene x physical activity interactions in obesity: combined analysis of 111,421 individuals of European ancestry', PLoS Genet, 9: e1003607. - PMC - PubMed
-
- Ahmed I, Lee PC, Lill CM, Searles Nielsen S, Artaud F, Gallagher LG, Loriot MA, Mulot C, Nacfer M, Liu T, Biernacka JM, Armasu S, Anderson K, Farin FM, Lassen CF, Hansen J, Olsen JH, Bertram L, Maraganore DM, Checkoway H, Ritz B, and Elbaz A. 2014. 'Lack of replication of the GRIN2A-by-coffee interaction in Parkinson disease', PLoS Genet, 10: e1004788. - PMC - PubMed
-
- Anand R, Gill KD, and Mahdi AA. 2014. 'Therapeutics of Alzheimer's disease: Past, present and future', Neuropharmacology, 76: 27–50. - PubMed
-
- Ascherio A, Zhang SM, Hernán MA, Kawachi I, Colditz GA, Speizer FE, Willett WC. 2001. 'Prospective study of caffeine consumption and risk of Parkinson's disease in men and women', Ann Neurol, 50: 56–63. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical